Technology ID
TAB-1011

ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders

E-Numbers
E-114-2004-0
Lead Inventor
Remaley, Alan
Co-Inventors
Neufeld, Edward (NHLBI)
Thomas, Fairwell (NHLBI)
Brewer, H. Bryan (NHLBI)
Demosky, Stephen (NHLBI)
Stonik, John (NHLBI)
Amar, Marcelo (NHLBI)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Endocrinology
Cardiology
Development Stages
Discovery
Lead IC
NHLBI
ICs
NHLBI
This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, aortic valve stenosis, atherosclerosis, carotid atherosclerosis, congestive heart failure, cerebral stroke, coronary artery disease, inflammation of the cardiovascular system, intermittent claudication, myocardial infarction, peripheral vascular disease, post-ischemic reperfusion, renal artery stenosis, reperfusion myocardial injury, restenosis, and thrombotic stroke.
Commercial Applications
  • Treatment and prevention of many hereditary, chronic and acute dyslipidemic and vascular disorders, where other treatments are not effective or too invasive, such as statins, partial ileal bypass surgery, portacaval shunt, liver transplantation, and removal of atherogenic lipoproteins by one of several apheresis procedures.
  • Also applicable to the treatment of inflammation, asthma, colitis, inflammatory bowel disease (IBD), chronic kidney disease (CKD).
Licensing Contact:
Davis, Michael
michael.davis4@nih.gov
Phone: 301-451-9032